Maxcyte (DI) (MXCT)

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 154.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 253.00
  • 52 Week Low: 154.00
  • Currency: UK Pounds
  • Shares Issued: 51.36m
  • Volume: 36
  • Market Cap: £79.09m
  • Beta: 0.01

MaxCyte launches new generation of cellular engineering instruments

By Duncan Ferris

Date: Monday 08 Apr 2019

LONDON (ShareCast) - (Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.
The medicines and life sciences company said the newly introduced products introduce updated software, a touch-screen user interface and other features that deliver a significant improvement to the user experience and will enable customers to standardize on a single, unifying technology from early research through to clinical and commercial use.

Brad Calvin, executive vice president of global commercial operations for MaxCyte, said: "The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies. Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies."

The AIM traded company said the new products build on a foundation of its solid technology and its past instrument platforms, which are used by all of the top ten biopharmaceutical companies by revenue.

Doug Doerfler, president and chief executive of MaxCyte, said: "We are proud to announce the launch of our next-generation ExPERT brand of instruments. We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases."

MaxCyte's shares were down 0.27% at 187.00p at 1143 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 154.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 253.00
52 Week Low 154.00
Volume 36
Shares Issued 51.36m
Market Cap £79.09m
Beta 0.01

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 19-Jun-2019

Time Volume / Share Price
16:21 36 @ 157.20p

Maxcyte (DI) Key Personnel

CEO Doug Doerfler
CFO Ron Holtz

Top of Page